Pebblebrook Hotel Trust heads into Thursday's Q2 results with its founder-CEO buying stock aggressively, short sellers rebuilding positions, and analysts collectively raising targets while mostly staying cautious.
The standout this week is the insider buying cluster. CEO Jon Bortz purchased 80,000 shares across five consecutive sessions in June, averaging prices between $16.84 and $18.18. The total spend was roughly $1.74 million net over 90 days. That kind of sustained, open-market accumulation from a founder-CEO is hard to dismiss as routine. Bortz sold 50,000 shares in December 2025 near $11.26, meaning the recent buys come at materially higher prices — and represent a conviction re-entry rather than a dip-add.
Short positioning tells a more cautious story about the broader market's read on PEB. Short interest has climbed to 15.4% of free float, up 16% over the past month and running near its highest level in the data window. The week-on-week build of around 2.7% is notable — shorts added around 240,000 shares since Monday. Yet the borrow market is not under stress. Cost to borrow runs just 0.52%, and availability is ample at roughly 405% of current short interest, well above the 52-week tightest reading of 151%. That means plenty of lending supply remains for anyone wanting to add or cover a position. The ORTEX short score is parked at 63.9, in the lower sixth percentile of the universe — a signal that short-side pressure is elevated relative to most names but not at an extreme that historically precedes forced covering. Options positioning is equally flat: the put/call ratio of 1.06 is essentially at its 20-day average, with a z-score near zero. There is no unusual hedging demand showing up ahead of the print.
Analyst moves this week crystallise the Street's split personality on this name. Citigroup raised its target sharply from $15 to $20 on July 22, maintaining Neutral — a notable catch-up move that now puts the Citi target in line with the current price. Barclays lifted its target from $13 to $15 on July 21 but kept its Underweight rating, and Morgan Stanley moved from $12 to $13 just days earlier, also holding Underweight. Truist is the outlier bull, running a $22 Buy. The mean analyst target is $17.55, which is below where the stock is now trading at $19.75 — a sign the Street has been chasing a stock that has outrun consensus. PEB has gained 5.6% this week and 3.6% over the past month, while close peers RLJ and XHR were up 5.5% and 5.7% respectively — the group has been broadly bid, so PEB's move is sector-driven rather than idiosyncratic. DRH led the pack at 7.2% on the week. The bull case rests on NAV recovery in San Francisco and stronger-than-expected EBITDA from legacy properties. The bear case points to lingering weakness in international inbound demand across Boston, Los Angeles, and San Francisco, and questions whether post-capex EBITDA gains materialise on the timeline management has guided to. EPS momentum ranks in just the 3rd percentile over both 30 and 90 days — the earnings revision trend has been weak even as the stock has moved higher.
Valuation is drifting into uncomfortable territory ahead of earnings. Price-to-book has risen to 0.93, up roughly 5% over the past month, while EV/EBITDA has edged to 13.2x. Both multiples are moving in the same direction as the share price — expanding, not compressing — which sharpens the stakes for Thursday's print. The prior earnings history offers some comfort: the last two quarterly reports produced next-day moves of -0.4% and +1.1%, and the five-day windows were modestly positive in both cases. History here suggests post-earnings volatility has been contained rather than dramatic.
With Q2 results due after the close on July 24, the key variable to watch is whether management's EBITDA guidance for the back half holds up given the softness in international urban demand — and whether Bortz's $1.7 million bet at prices above $17 starts to look prescient or premature.
See the live data behind this article on ORTEX.
Open PEB on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
